Showing results (1-10 of 331) with videos related to
Sort By:
Pageof 34
The Oncologist|June 22, 2005
Risk models for predicting chemotherapy-induced neutropeniaGary H Lyman, Christopher H Lyman, Olayemi AgboolaCancer Control : Journal of the Moffitt Cancer Center|December 4, 2003
Evidence-based use of colony-stimulating factors in elderly cancer patientsGary H Lyman, Nicole Kuderer, Olayemi Agboola, et al.Pharmacotherapy|April 22, 2004
Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapyLeon E Cosler, Elizabeth A Calhoun, Olayemi Agboola, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 22, 2005
Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapyLeon E Cosler, Visaharan Sivasubramaniam, Olayemi Agboola, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
New Biosimilar Approvals for Myeloid Growth Factors and AnemiaGary H LymanCurrent Opinion in Hematology|November 3, 2010
A comparison of international guidelines for the prevention of chemotherapy-induced neutropeniaGary H LymanOncology (Williston Park, N.Y.)|December 20, 2003
Risk assessment in oncology clinical practice. From risk factors to risk modelsGary H LymanSeminars in Oncology|September 26, 2003
Balancing the benefits and costs of colony-stimulating factors: a current perspectiveGary H LymanClinical Cornerstone|March 24, 2007
Risks and consequences of chemotherapy-induced neutropeniaGary H LymanOncology (Williston Park, N.Y.)|August 24, 2006
Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemiaGary H LymanPageof 34